EurekAlert!

One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment in 4,000-patient study over 10 years

Brussels, Belgium – 7 mai 2025: Presented at ESTRO 2025, which gathered a record attendance of 7,908 participants this week in Vienna, Austria, a 10-year study, involving over 4,000 UK patients, ...

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast ...

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s ...
Cure Today

FDA Fast Tracks Vaccine For Some With Breast Cancer

GLSI-100 has received FDA fast track designation for HLA-A*02-positive and HER2-positive breast cancer, expediting its development and review process. Preliminary data from the FLAMINGO-01 trial shows ...
PharmiWeb

More early breast cancer patients, at high risk of recurrence, gain access to Novartis’ Kisqali® (ribociclib) as the treatment is accepted for use in Scotland

The Scottish Medicines Consortium (SMC) announced today that they have accepted Kisqali (ribociclib) for use within NHS Scotland as an adjuvant treatment option in combination with an aromatase ...